Bone Grafts Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Grafts, including details on spine fusion, surgery, procedure, risks. | ||||||||
|
Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplants but does not impact chronic GVHD incidence.Battiwalla M, Hahn T, Radovic M, Roy H, Wahab A, Duman E, Bajwa R, Padmanabhan S, Becker J, Barrett AJ, McCarthy Jr PL Departments of Medicine and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. TThe DR15 allele at the HLA DRB1 locus is a marker for immune-mediated bone marrow failure syndromes. We hypothesized that HLA DR15 plays a role in T-cell interactions with hematopoiesis and investigated the role of HLA DR15 on graft-versus-host disease (GVHD) and graft-versus-leukemia effects in HLA-matched allogeneic blood or marrow transplants (BMT) performed for myeloid malignancies. We performed a retrospective analysis of 119 consecutive related and 48 consecutive unrelated allogeneic BMTs for myeloid malignancies treated between 1991 and 2005 to investigate the influence of HLA DR15 on overall survival (OS), progression-free survival (PFS) and incidence of grade II-IV acute GVHD. HLA DR15 was determined by either molecular (n=108) or serologic (n=59) methods. The incidence of HLA DR15 was similar to the general Caucasian population (35/167=21%). There were no significant differences in transplant characteristics between the HLA DR15 positive and negative groups. There was no significant difference in chronic GVHD, OS or PFS between the HLA DR15 positive vs. negative groups in any disease or donor relation subgroups. The HLA DR15 positive group experienced a significantly lower incidence of acute GVHD grade II-IV: 23% vs. 42%, p=0.041. These results suggest that HLA DR15 reduces the risk of acute GVHD. Published 11 November 2005 in Blood.
© 2004-2008 Bone Grafts Research Today. All Rights Reserved. |
| ||||||
